FORA Capital LLC Grows Position in Hims & Hers Health, Inc. $HIMS

Key Points

• FORA Capital LLC increased its stake in Hims & Hers Health by 22.7%, owning approximately $5 million in shares as of its latest SEC filing.
• Insider sales amounted to a total of 1,392,857 shares valued at nearly $72 million over the last three months, indicating a 26.09% ownership decrease by insider Patrick Harrison Carroll.
• Hims & Hers Health reported a quarterly revenue of $544.83 million, which was below the consensus estimate, while their stock has experienced a 3.5% decline recently.

FORA Capital LLC increased its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 22.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 170,679 shares of the company's stock after acquiring an additional 31,540 shares during the quarter. FORA Capital LLC owned approximately 0.08% of Hims & Hers Health worth $5,044,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. UMB Bank n.a. lifted its stake in Hims & Hers Health by 247.5% in the first quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after acquiring an additional 933 shares during the period. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Hims & Hers Health in the first quarter worth about $41,000. Larson Financial Group LLC lifted its stake in Hims & Hers Health by 47.7% in the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock worth $42,000 after acquiring an additional 458 shares during the period. Fifth Third Bancorp lifted its stake in Hims & Hers Health by 165.4% in the first quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock worth $46,000 after acquiring an additional 961 shares during the period. Finally, Tsfg LLC purchased a new stake in Hims & Hers Health in the first quarter worth about $46,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Zacks Research downgraded shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Piper Sandler reiterated a "neutral" rating and issued a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Two investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Hims & Hers Health has a consensus rating of "Reduce" and a consensus target price of $38.92.

Insider Transactions at Hims & Hers Health

In related news, insider Michael Chi sold 2,100 shares of the company's stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $57.52, for a total value of $120,792.00. Following the sale, the insider owned 278,654 shares in the company, valued at $16,028,178.08. This represents a 0.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Patrick Harrison Carroll sold 60,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total value of $3,214,800.00. Following the completion of the sale, the insider owned 169,940 shares in the company, valued at approximately $9,105,385.20. This represents a 26.09% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,383,847 shares of company stock worth $71,247,924 in the last ninety days. Corporate insiders own 13.71% of the company's stock.

Hims & Hers Health Stock Down 2.8%

Shares of HIMS traded down $1.28 during mid-day trading on Wednesday, hitting $44.07. 19,794,523 shares of the company traded hands, compared to its average volume of 32,739,814. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The company has a market capitalization of $9.96 billion, a PE ratio of 55.09, a price-to-earnings-growth ratio of 3.06 and a beta of 2.08. The business has a 50 day moving average of $50.76 and a 200 day moving average of $45.84.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business's revenue was up 72.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.